RB1 and non-small cell lung carcinoma: Collectively, comprehensive molecular profiling of acquired RET + patients showed that co-existing genomic alterations, such as TP53 and RB1 co-mutations and ERBB2 amplification, might be associated with a poor prognosis in EGFR-mutated NSCLC patients upon drug resistance.